Daina Graybosch
Stock Analyst at Leerink Partners
(1.18)
# 2,676
Out of 4,479 analysts
100
Total ratings
37.04%
Success rate
-10.43%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.74 | +36.05% | 8 | May 15, 2024 | |
| TSVT 2seventy bio | Upgrades: Outperform | $5 → $18 | $3.86 | +366.32% | 5 | Jan 31, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $53.25 | -26.76% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $1.17 | +156.41% | 7 | Feb 24, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $120 → $122 | $127.72 | -4.48% | 15 | Feb 3, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $2.21 | +533.48% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $3.22 | +210.56% | 6 | Jan 6, 2023 | |
| AFMD Affimed | Maintains: Outperform | $100 → $60 | $5.16 | +1,063.92% | 7 | Dec 12, 2022 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $2.06 | +336.89% | 9 | Nov 15, 2022 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $40 → $38 | $14.65 | +159.39% | 2 | Nov 3, 2022 | |
| LVTX LAVA Therapeutics | Maintains: Outperform | $25 → $28 | $1.87 | +1,397.33% | 5 | Sep 27, 2022 | |
| MOLN Molecular Partners AG | Downgrades: Market Perform | $30 → $8 | $7.00 | +14.29% | 4 | Aug 29, 2022 | |
| BNTX BioNTech SE | Maintains: Outperform | $223 → $224 | $78.76 | +184.41% | 13 | Jul 29, 2022 | |
| NKTX Nkarta | Initiates: Outperform | $30 | $5.26 | +470.34% | 1 | Jul 18, 2022 | |
| ITOS iTeos Therapeutics | Maintains: Outperform | $60 → $59 | $14.44 | +308.59% | 4 | May 13, 2022 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $18 → $17 | $2.06 | +725.24% | 3 | May 11, 2022 | |
| CGEN Compugen | Maintains: Outperform | $16 → $9 | $1.69 | +432.54% | 2 | Feb 25, 2022 |
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.74
Upside: +36.05%
2seventy bio
Jan 31, 2024
Upgrades: Outperform
Price Target: $5 → $18
Current: $3.86
Upside: +366.32%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $53.25
Upside: -26.76%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $1.17
Upside: +156.41%
Merck & Co.
Feb 3, 2023
Maintains: Outperform
Price Target: $120 → $122
Current: $127.72
Upside: -4.48%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $2.21
Upside: +533.48%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $3.22
Upside: +210.56%
Affimed
Dec 12, 2022
Maintains: Outperform
Price Target: $100 → $60
Current: $5.16
Upside: +1,063.92%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.06
Upside: +336.89%
Arcus Biosciences
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $14.65
Upside: +159.39%
LAVA Therapeutics
Sep 27, 2022
Maintains: Outperform
Price Target: $25 → $28
Current: $1.87
Upside: +1,397.33%
Molecular Partners AG
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $7.00
Upside: +14.29%
BioNTech SE
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $78.76
Upside: +184.41%
Nkarta
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $5.26
Upside: +470.34%
iTeos Therapeutics
May 13, 2022
Maintains: Outperform
Price Target: $60 → $59
Current: $14.44
Upside: +308.59%
Werewolf Therapeutics
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $2.06
Upside: +725.24%
Compugen
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.69
Upside: +432.54%